Summit Therapeutics Inc (SMMT)
followers
·
Follow
1 like
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Robert W. Duggan |
| Employees: | 110 |
| Web site: | summittxinc.com |
|
601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131
305-203-2034
| |
-
Formally known as:
- SUMMIT THERAPEUTICS ORD SHS
- Summit Therapeutics PLC
- Summit Therapeutics plc ADR
Are you looking for this stock instead?
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Summit Therapeutics Inc. conducts clinical programs focusing on Clostridioides difficile infection (CDI) The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Please log in first to see chart